Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Fesoterodine Fumarate (SPM907; Toviaz, SPM-907), the fumarate salt of Fesoterodine which is a prodrug of 5-hydroxymethyl tolterodine, is a muscarinic AChR receptor antagonist that has been approved for treating overactive bladder syndrome.
ln Vitro |
Fesoterodine fumarate raises the volume expelled with each micturition while reducing the frequency, intensity, and urgency of incontinence episodes[1]. Following oral administration, nonspecific esterases quickly and completely hydrolyze fesoterodine fumarate in plasma to produce desfesoterodine, an active metabolite of fesoterodine (5-hydroxymethyl tolterodine; SPM 7605 ; HY-76569)[3][4].
|
---|---|
ln Vivo |
At the lowest studied dose of 0.01 mg/kg, fesoterodine fumarate (0.01-1 mg/kg; IV) decreases micturition pressure, increases bladder capacity, and increases ICIs (intercontraction intervas)[3].
|
Animal Protocol |
Animal/Disease Models: Bladders from female SD (Sprague-Dawley) rats (225-275 g)[3]
Doses: 0.01, 0.1 and 1 mg/kg Route of Administration: IV Experimental Results: decreased the micturition pressure and increased bladder capacity and ICIs at the lowest dose tested of 0.01 mg/kg. |
References |
[1]. Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18.
[2]. Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats. [3]. Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr;101(8):1036-42. [4]. Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. |
Molecular Formula |
C26H37NO3.C4H4O4
|
|
---|---|---|
Molecular Weight |
527.65
|
|
CAS # |
286930-03-8
|
|
Related CAS # |
Fesoterodine;286930-02-7;Fesoterodine-d7 fumarate;2747918-94-9
|
|
SMILES |
OCC1=CC([C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2)=C(C=C1)OC(C(C)C)=O.OC(/C=C/C(O)=O)=O
|
|
InChi Key |
MWHXMIASLKXGBU-RNCYCKTQSA-N
|
|
InChi Code |
InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1
|
|
Chemical Name |
(E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8952 mL | 9.4760 mL | 18.9520 mL | |
5 mM | 0.3790 mL | 1.8952 mL | 3.7904 mL | |
10 mM | 0.1895 mL | 0.9476 mL | 1.8952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.